adults

EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30…

1 week ago

Manipal Hospital Yeshwanthpur Leads the Charge as Heart Attacks in Young Indians Reach Crisis Levels

BENGALURU, India, July 17, 2025 /PRNewswire/ -- India is witnessing an alarming public health crisis with heart attacks increasingly striking…

1 week ago

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals…

1 month ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

1 month ago

HealthRX Expands Telehealth Website Experience to Include GLP-1 Weight Loss Solutions, Prescription Access, and 24/7 Wellness Support

BROOKLYN, June 19, 2025 (GLOBE NEWSWIRE) -- HealthRX, a digital health platform serving adults across the United States, has announced…

1 month ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032

FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food…

2 months ago

Ro Weight Loss Announces Official Website Update Featuring Natural Daily Program for Medically-Guided Weight Management

New York, June 07, 2025 (GLOBE NEWSWIRE) -- Ro Weight Loss, a digital health service from Roman Health Ventures Inc.,…

2 months ago

Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of 4.00

Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of…

2 months ago